Table 1

Baseline characteristics of patients with TAK included in the study

Total (n=1065)Patients who had a stroke (n=73)Patients who had no stroke (n=992)P value
Age at diagnosis (years)46.7±15.049.5±13.446.5±15.20.101
 <2051 (4.8)3 (4.1)48 (4.8)0.116
 20–29113 (10.6)1 (1.4)112 (11.3)
 30–39146 (13.7)12 (16.4)134 (13.5)
 40–49263 (24.7)18 (24.7)245 (24.7)
 50–59280 (26.3)26 (35.6)254 (25.6)
 60–69152 (14.3)8 (11.0)144 (14.5)
 ≥7060 (5.6)5 (6.8)55 (5.6)
Sex, n (%)0.518
 Female867 (81.4)62 (84.9)805 (81.1)
 Male198 (18.6)11 (15.1)187 (18.9)
Type of insurance, n (%)0.157
 National Health Insurance1034 (97.1)69 (94.5)965 (97.3)
 Medical aid31 (2.9)4 (5.5)27 (2.7)
Comorbidities
Hypertension0.904
 No569 (53.4)40 (54.8)529 (53.3)
 Yes496 (46.6)33 (45.2)463 (46.7)
Diabetes mellitus0.924
 No858 (80.6)58 (79.4)800 (80.6)
 Yes207 (19.4)15 (20.6)192 (19.4)
Dyslipidaemia0.436
 No544 (51.1)41 (56.2)503 (50.7)
 Yes521 (48.9)32 (43.8)489 (49.3)
Atrial fibrillation and flutter0.303
 No1029 (96.6)69 (94.5)960 (96.8)
 Yes36 (3.4)4 (5.5)32 (3.2)
Administered medication
Immunosuppressive treatments
 Glucocorticoid treatment ≥3 months538 (50.5)16 (21.9)522 (52.6)<0.001
 Azathioprine201 (18.9)6 (8.2)195 (19.7)0.024
 Methotrexate366 (34.4)11 (15.1)355 (35.8)<0.001
Antiplatelet therapy
 Aspirin655 (62.4)31 (42.5)634 (63.9)<0.001
 Clopidogrel299 (28.1)16 (21.9)283 (28.5)0.281
 Statins610 (57.3)25 (34.3)585 (59.0)<0.001
 Follow-up duration (years)4.29 (2.66)1.44 (2.06)4.51 (2.57)<0.001
  • Values are shown as mean (SD) or number (percentages).

  • TAK, Takayasu arteritis.